Error message

Deprecated function: The each() function is deprecated. This message will be suppressed on further calls in menu_set_active_trail() (line 2405 of /home/hulijedw/public_html/includes/menu.inc).

Novavax Calls Bird Flu Vaccine Trial Results Favorable

erku's picture

Novavax, Inc. (Nasdaq: NVAX) today held an investor conference call to discuss results from the Phase I/IIa human clinical trial of Novavax’s H5N1 pandemic influenza VLP vaccine candidate at 11:00. This was a big news about the first favorable results in the search of bird flu vaccine for humans.

During the conference call Novavax presented the VLP bird flu vaccine information and said "Novavax, Inc. (NASDAQ: NVAX) announced today favorable results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, induced robust neutralizing antibody responses. Novavax's VLP candidate is directed against the H5N1 A/Indonesia/05/2005 avian influenza strain. Avian influenza emerged in humans in Indonesia in 2005 and has caused 135 documented human cases, 81% of which have been fatal."

The call was hosted by Novavax President and Chief Executive Officer Dr. Rahul Singhvi and other members of senior management, including Chief Medical Officer, Dr. Penny Heaton. A question and answer session was follow the presentation of the bird flu vaccine data.

Novavax basically said that this experimental bird flu vaccine on humans works and has produced a strong immune response in humans.

“These data are exciting because they demonstrate that recombinant VLPs are a valid and potent vaccine approach against influenza. Combined with our innovative manufacturing approach, our VLP vaccine candidate has the potential to address an unmet need in pandemic influenza preparedness efforts being planned by health authorities around the world,” said Dr. Rahul Singhvi, President and CEO of Novavax.

Add new comment